The Need to Accelerate Access to New Drugs for Multidrug-resistant Tuberculosis

Hdl Handle:
http://hdl.handle.net/10144/560858
Title:
The Need to Accelerate Access to New Drugs for Multidrug-resistant Tuberculosis
Authors:
Cox, Helen S; Furin, Jennifer J; Mitnick, Carole D; Daniels, Colleen; Cox, Vivian; Goemaere, Eric
Journal:
Bulletin of the World Health Organization
Abstract:
Approximately half a million people are thought to develop multidrug-resistant tuberculosis annually. Barely 20% of these people currently receive recommended treatment and only about 10% are successfully treated. Poor access to treatment is probably driving the current epidemic, via ongoing transmission. Treatment scale-up is hampered by current treatment regimens, which are lengthy, expensive, poorly tolerated and difficult to administer in the settings where most patients reside. Although new drugs provide an opportunity to improve treatment regimens, current and planned clinical trials hold little promise for developing regimens that will facilitate prompt treatment scale-up. In this article we argue that clinical trials, while necessary, should be complemented by timely, large-scale, operational research that will provide programmatic data on the use of new drugs and regimens while simultaneously improving access to life-saving treatment. Perceived risks - such as the rapid development of resistance to new drugs - need to be balanced against the high levels of mortality and transmission that will otherwise persist. Doubling access to treatment and increasing treatment success could save approximately a million lives over the next decade.
Publisher:
World Health Organization
Issue Date:
1-Jul-2015
URI:
http://hdl.handle.net/10144/560858
DOI:
10.2471/BLT.14.138925
PubMed ID:
26170507
Language:
en
ISSN:
1564-0604
Appears in Collections:
TB

Full metadata record

DC FieldValue Language
dc.contributor.authorCox, Helen Sen_GB
dc.contributor.authorFurin, Jennifer Jen_GB
dc.contributor.authorMitnick, Carole Den_GB
dc.contributor.authorDaniels, Colleenen_GB
dc.contributor.authorCox, Vivianen_GB
dc.contributor.authorGoemaere, Ericen_GB
dc.date.accessioned2015-07-21T22:50:21Z-
dc.date.available2015-07-21T22:50:21Z-
dc.date.issued2015-07-01-
dc.identifier.citationThe need to accelerate access to new drugs for multidrug-resistant tuberculosis. 2015, 93 (7):491-7 Bull. World Health Organ.en_GB
dc.identifier.issn1564-0604-
dc.identifier.pmid26170507-
dc.identifier.doi10.2471/BLT.14.138925-
dc.identifier.urihttp://hdl.handle.net/10144/560858-
dc.description.abstractApproximately half a million people are thought to develop multidrug-resistant tuberculosis annually. Barely 20% of these people currently receive recommended treatment and only about 10% are successfully treated. Poor access to treatment is probably driving the current epidemic, via ongoing transmission. Treatment scale-up is hampered by current treatment regimens, which are lengthy, expensive, poorly tolerated and difficult to administer in the settings where most patients reside. Although new drugs provide an opportunity to improve treatment regimens, current and planned clinical trials hold little promise for developing regimens that will facilitate prompt treatment scale-up. In this article we argue that clinical trials, while necessary, should be complemented by timely, large-scale, operational research that will provide programmatic data on the use of new drugs and regimens while simultaneously improving access to life-saving treatment. Perceived risks - such as the rapid development of resistance to new drugs - need to be balanced against the high levels of mortality and transmission that will otherwise persist. Doubling access to treatment and increasing treatment success could save approximately a million lives over the next decade.en_GB
dc.language.isoenen
dc.publisherWorld Health Organizationen_GB
dc.rightsArchived with thanks to Bulletin of the World Health Organizationen_GB
dc.titleThe Need to Accelerate Access to New Drugs for Multidrug-resistant Tuberculosisen
dc.identifier.journalBulletin of the World Health Organizationen_GB

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.